EGFR and non-small cell lung carcinoma: Research investigating the mechanisms of action of EGFR TKIs in both EGFR wild-type and EGFR mutant NSCLC has revealed that these inhibitors function by inhibiting the intracellular phosphorylation of the EGFR protein, particularly in T790M mutant variants [29].